October Upside Ranks
Qualitative relative target-touch selections · Not calibrated probabilities
Dated prices · targets are price touches, not forecasts · exact ranks are editorial judgments.
Grade legend, dates & research limits
Completed editorial grades · assessed October 6. Business = demonstrated commercial traction. Catalyst = clarity and timing of the next important test, not success odds. Target path = how demanding this list’s target is. These grades use the same rubric for all selected names; they are not native financial-model grades or statistical probabilities.
A strong / direct · B supported but conditional · C speculative or major gaps · D exceptional leap / weak bridge. A strong catalyst can fail. A fivefold target can have a D path even in a top-ranked moonshot.
Exact grading benchmarks & evidence dates
Business
How far the business inflection is demonstrated today, not source completeness.
- A — Broad, realized commercial growth or earnings; not just a plan.
- B — Real but early, concentrated or mixed operating traction.
- C — Primarily clinical/development or capacity optionality; limited realized economics.
- D — Retained facts undermine the proposed business inflection.
Catalyst
Specificity, observability and timing of a thesis-changing test inside the original window, not its chance of success.
- A — A scheduled or explicitly windowed material readout, launch or commercial ramp; repeated hard operating tests may qualify.
- B — Concrete delivery, orders or earnings tests, but diffuse timing or less discrete thesis change.
- C — A real milestone with important acceptance/economics/timing gaps.
- D — No supported material in-window test.
Target path
Burden of reaching THIS tier target from the dated baseline; not an absolute odds estimate.
- A — Comparatively direct earnings/recognition bridge in retained evidence; still conditional.
- B — Recognizable bridge, but meaningful premium, execution or share-claim sensitivity.
- C — Speculative extension or binary rerating beyond established economics; small-base elasticity is not a forecast.
- D — Exceptional leap far beyond retained cases, with major scale/valuation/financing obstacles.
No bell curve, numeric weights, A+ grades, probability conversion or grade-based reranking. Same rubric for incumbents and additions; target-path grades vary by tier. A catalyst can fail. No synchronized chart grading because technical coverage is not comparable across all 19.
Assessment October 6 of retained evidence, not an October 6 source refresh. Baseline October 1; existing remaining touch window October 4, 2026 to exclusive October 1, 2027. Original source cutoff October 3; additions retrieved October 4; Bloom narrative retrieved October 5 UTC. Original publication dates remain attached to sources.
Original conservative research grades remain in each full story. Partial financial underwriting remains partial: completed qualitative grades do not certify current cash, target dilution, clinical efficacy or funded forecasts. No chart grade is invented from unmatched technical snapshots.
Targets use October 1, 2026 baseline quotes, which are not live prices. The price-touch window is October 4, 2026 to exclusive October 1, 2027, not the price at expiry. Exact ordinal differences are low-confidence editorial judgments; absolute likelihood may be low.
Original financial source cutoff: October 3, 2026, 07:14:12.687379 UTC. Biotech sources retrieved October 4 with original publication dates retained. Bloom’s power and policy narrative reviewed October 4 ET (sources retrieved October 5 UTC). Publication does not clear research or model limitations. No calibrated odds.
RXRX · Recursion
2x Conviction · #10Oct1 baseline: USD 4.07. Historical daily quote retrieved Oct4.
The investment story
Thesis
November clinical results and partner milestones could strengthen confidence in Recursion’s drug platform, even before recurring drug sales exist.
What could move the stock
November clinical results and partner milestones could strengthen confidence in Recursion’s drug platform, even before recurring drug sales exist.
Next catalyst
REC-4881 safety and efficacy update scheduled for November 2, 2026.
Major risk
Early clinical results may disappoint; cash burn and irregular milestone payments remain risks.
Editorial grades · October 6 assessment
Same rubric for every selected company. Business is demonstrated traction; Catalyst is the timing and clarity of a test, not its chance of success. Target path changes with the target burden.
2x Conviction
Business · C
Partner validation and early human activity support discovery potential, but falling milestone revenue is not recurring product demand.
Catalyst · A
The November 2, 2026 REC-4881 update is a specific scheduled readout; it is not randomized causal efficacy proof.
Target path · C
Multiple clinical tests could reprice the platform, but early data and irregular milestones do not establish a funded double bridge.
Strongest countercase
Early clinical disappointment, cash burn and irregular milestones remain major risks.
Confidence & coverage
Low for target touch and adjacent ordering; moderate for the descriptive assessment of retained facts. Partial financial underwriting; current cash and target-dependent dilution unresolved.
Grade evidence & preserved research grades
Editorial reader v2 is separate from native financial certification. The original conservative evidence/path grades below have not been upgraded or overwritten.
2x Conviction original research grades
Evidence: not supplied; operating pathway: not supplied; feasibility: not supplied.
- RXRX-10Q
Published: 2026-08-05 · Retrieved: 2026-10-04T14:05:02.306247+00:00 - RXRX-facts
Published: Unknown — undated / publication time not supplied · Retrieved: 2026-10-04T14:05:02.306507+00:00 - RXRX-latest8K
Published: 2026-09-21 · Retrieved: 2026-10-04T14:06:42.413570+00:00 - RXRX-sept8K
Published: Unknown — undated / publication time not supplied · Retrieved: 2026-10-04T14:05:02.917755+00:00 - RXRX-submissions
Published: Unknown — undated / publication time not supplied · Retrieved: 2026-10-04T14:04:38.146583+00:00
Detailed research, financial evidence & sources
Business
AI-native drug platform; collaboration milestones and clinical assets, not recurring drug sales.
Financial quality
H1 revenue fell from $33.968m to $14.143m. Genentech target option is early discovery validation, not approved medicine or product sale. Company explicitly expects no product-candidate sales for at least several years.
Claims and dilution
Cover Class A 535.342170m excludes 0.928917m June30 exchangeable economic shares; current exchangeable count unknown. June30 total economic shares 534.120235m. 27.468075m unvested RSUs are gross contingent claims, not all incremental Oct4 dilution. $300m ATM available June30, none sold H1. Tempus amended Sept15: $14m annual fees third/fourth/fifth anniversaries, at least $4m cash each, remainder cash/shares; no double-counting old $42m obligation. $12m TxFM license fee in two $6m installments due execution/first anniversary; due is not received.
Guide / interpretation
No quantified latest burn guide used; annualized H1 FCF diagnostic is not management guidance.
Countercase
Cost base declined materially vs H1 2025, with lower cash use; major partner validates target maps. Multiple independent catalysts can reprice platform without drug sales.
Concrete catalysts — not efficacy promises
- REC-4881 TUPELO Phase1b/2 updated safety/efficacy, contextualized with real-world registry data, scheduled CGA-IGC Nov2 2026 13:30-15:00 MST; sponsor-reported prior human activity, not randomized causal efficacy proof or approval.
- REC-4881 FDA registrational-path update expected 2H26; not approval.
- REC-1245 additional Phase1 dose escalation data expected 2H26.
- REC-617 and REC-3565 early Phase1 safety/PK expected 1H27. REC-4539 2H27 partially outside horizon.
- REC-7735 IND cleared; ZINNIA Phase1/2 initiation expected2H26, not achieved by assertion.
Dated reported financial evidence
US GAAP unaudited consolidated; flows 2026-01-01 through2026-06-30 inclusive; stocks June30 unless dated share cover. Units: reported USD millions unless a share count, ratio or date is explicitly named. These are not October 4 bank balances.
- cash
- 545.683
- securities
- Unknown (null)
- liquid
- 545.683
- restricted
- 11.137
- debt
- Unknown (null)
- debt and finance lease
- 14.196
- op leases
- 52.442
- revenue
- 14.143
- operating income
- -263.472
- net income
- -248.509
- ocf
- -187.048
- capex
- 0.302
- sbc ocf
- 41.713
- sbc expense
- 41.3
- shares
- 535,342,170
- share date
- 2026-07-31
- weighted
- 530,890,753
- rsus
- 27,468,075
- options
- Unknown (null)
Target burdens — static sensitivities, not forward fair value
Static reverse burden not forward fairvalue/funded hitcase; unknown actual current claims/cash not replaced by these dated balances.
1.35× baseline · USD 5.495
latest dated common-only
historical stocks; elapsed stub and target awards unknown · NO target price-dependent conversion/award claim solved; leases not appended to lease-expensed revenue valuation; no terminal cash implied
- datedSharesM
- 535.342
- datedLiquidityUSDm
- 545.683
- datedDebtUSDm
- Unknown (null)
- requiredCommonEquityUSDm
- 2,941.438
- staticEVUSDm
- Unknown (null)
July ClassA plus June exchangeable proxy
mixed dated classes, proxy not currentcap table · NO target price-dependent conversion/award claim solved; leases not appended to lease-expensed revenue valuation; no terminal cash implied
- datedSharesM
- 536.271
- datedLiquidityUSDm
- 545.683
- datedDebtUSDm
- Unknown (null)
- requiredCommonEquityUSDm
- 2,946.542
- staticEVUSDm
- Unknown (null)
2× baseline · USD 8.14
latest dated common-only
historical stocks; elapsed stub and target awards unknown · NO target price-dependent conversion/award claim solved; leases not appended to lease-expensed revenue valuation; no terminal cash implied
- datedSharesM
- 535.342
- datedLiquidityUSDm
- 545.683
- datedDebtUSDm
- Unknown (null)
- requiredCommonEquityUSDm
- 4,357.685
- staticEVUSDm
- Unknown (null)
July ClassA plus June exchangeable proxy
mixed dated classes, proxy not currentcap table · NO target price-dependent conversion/award claim solved; leases not appended to lease-expensed revenue valuation; no terminal cash implied
- datedSharesM
- 536.271
- datedLiquidityUSDm
- 545.683
- datedDebtUSDm
- Unknown (null)
- requiredCommonEquityUSDm
- 4,365.247
- staticEVUSDm
- Unknown (null)
5× baseline · USD 20.35
latest dated common-only
historical stocks; elapsed stub and target awards unknown · NO target price-dependent conversion/award claim solved; leases not appended to lease-expensed revenue valuation; no terminal cash implied
- datedSharesM
- 535.342
- datedLiquidityUSDm
- 545.683
- datedDebtUSDm
- Unknown (null)
- requiredCommonEquityUSDm
- 10,894.214
- staticEVUSDm
- Unknown (null)
July ClassA plus June exchangeable proxy
mixed dated classes, proxy not currentcap table · NO target price-dependent conversion/award claim solved; leases not appended to lease-expensed revenue valuation; no terminal cash implied
- datedSharesM
- 536.271
- datedLiquidityUSDm
- 545.683
- datedDebtUSDm
- Unknown (null)
- requiredCommonEquityUSDm
- 10,913.117
- staticEVUSDm
- Unknown (null)
Target-specific terminal shares: Unknown (null). Target-specific terminal cash: Unknown (null).
Discovery chart context
recovery · QQQ-relative discovery only, separate from AI100 runtime SPY scoring. Retained Oct1/Oct2 observations retrieved Oct4; no numerical rank against all incumbents.
- return20d
- 0.183
- return60d
- 0.082
- return120d
- 0.19
- distanceHigh
- -0.433
- range20d
- 0.384
- relative60d
- 0.055
Risks and unresolved inputs
- Oct4 actual liquid balances
- Target-dependent dilution and future issuance
- Market expectations baseline
- Exact forecast peak cash
2x Conviction strongest countercase
TER delivered a merchant-GPU order and has genuine hyperscaler qualification/operating leverage. RXRX remains43.31% below its high, uses ~$378.690m annualized H1 cash after PPE/intangibles, and $8.14 requires ~$4.358bn dated ClassA equity. Nov2 data are not randomized proof or approval.
- RXRX-10Q
Published: 2026-08-05 · Retrieved: 2026-10-04T14:05:02.306247+00:00 - RXRX-facts
Published: Unknown — undated / publication time not supplied · Retrieved: 2026-10-04T14:05:02.306507+00:00 - RXRX-latest8K
Published: 2026-09-21 · Retrieved: 2026-10-04T14:06:42.413570+00:00 - RXRX-sept8K
Published: Unknown — undated / publication time not supplied · Retrieved: 2026-10-04T14:05:02.917755+00:00 - RXRX-submissions
Published: Unknown — undated / publication time not supplied · Retrieved: 2026-10-04T14:04:38.146583+00:00